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Anemias 
Definition of anemia  
• Anemia is best defined in relation to H&H 
(hemoglobin [Hb] and hematocrit [HCT]) levels below 
the normal reference range, because a patient’s 
symptoms and physiologic consequences are the 
result of decreased oxygen-carrying capacity of the 
blood.  
• According to World Health Organization (WHO) 
criteria, anemia is diagnosed in males when Hb is 
<130 g/L (13 g/dL) and HCT is <0.39 (39%); in 
nonpregnan females, when Hb is <120 g/L (12 g/dL) 
and HCT is <0.36 (36%). 
Hematocrit evaluation in anemia 
The diagram illustrates that a person can have a low 
hematocrit and not be anemic. This occurs when a patient 
is overhydrated, typically as a result of overenthusiastic 
intravenous fluid therapy. 
Pathological classification of 
anemias • Blood loss 
 Acute 
 Chronic  
• Decreased production 
 Deficiency anaemias 
 Iron deficiency 
Vitamin B12 and Folate deficiency 
 Bone marrow disease/infiltration 
• Increased destruction 
Inherited (Membrane, enzyme,  Hb defects) 
Acquired (immune and non-immune)  
 
 Classification of anemias by 
mean cell volume (MCV) 
http://www.hem-
aids.ru/system/files/attachments/646
/anemii_anemii_pdf_008.pdf 
Classification of anemias by mean 
cell hemoglobin (MCH) 
 • MCH  represents the average content of Hb in 
average RBC.   
I. Hypochromic anemia <27 picograms/cell 
 
II. Hyperchromic anemia >31 picograms/cell 
 
III. Normochromic anemia 27 - 31 picograms/cell 
 
Classification of anemia according 
to the degree of severity  
1. Mild - hemoglobin - 120-90 g /l 
2. Moderate - hemoglobin - 90-70 g /l 
3. Severe - hemoglobin - less than 70 g / l  
 
Anisocytosis and poikilocytosis 
• Normally all red blood cells are relatively 
uniform in size and shape.  
• Variation in size is referred to as “anisocytosis”  
• Variation in shape is is referred to as 
“poikilocytosis” 
IRON DEFICIENCY 
and  
IRON DEFICIENCY ANAEMIA 
Definition 
• Iron deficiency will result from any condition in 
which dietary iron intake does not meet the 
body's demands.  
• Iron deficiency anemia is characterized by a 
defect in hemoglobin synthesis, resulting in red 
blood cells that are abnormally small 
(microcytic) and contain a decreased amount of 
hemoglobin (hypochromic). 
Epidemiology  
• Iron deficiency anemia (IDA) is a disease that is potentially 
exposed to people of all ages, both sexes, all socio-economic 
classes and geographic regions. 
• However, the most prone to IDA are pregnant women, women of 
reproductive age and children under school age, and patients with 
low socio-economic status. 
• According to the report of the World Health Organization  anemia 
affects 1.6 billion people, accounting for 24.8% of the global 
population.  
• The highest prevalence of IDA in the world has seen in Africa and 
South East Asia.  
• In India, for example, up to 88% of pregnant and 74% of non-
pregnant women are affected. Throughout Africa, about 50% of 
pregnant and 40% of non-pregnant women are anaemic. West 
Africa is the most affected, and southern Africa the least. 
International Statistical Classification of 
Diseases (ICD-10) 
Iron deficiency is coded as: 
•  (E61.1) Iron deficiency 
Iron deficiency anemia is coded as: 
• (D50) Iron deficiency anaemia  
• (D50.0) Iron deficiency anaemia secondary to blood 
loss (chronic) 
• (D50.1) Sideropenic  dysphagia  
• Kelly-Paterson syndrome 
• Plummer-Vinson syndrome 
• (D50.8) Other iron deficiency anaemias 
• (D50.9) Iron deficiency anaemia, unspecified 
Classification 
  Causes of Iron Deficiency and Iron Deficiency Anaemia  
 Increased Requirements Decreased Intake 
Growing infants and children  
Menstruating women  
Pregnancy 
Lactation  
Multiparity  
Parturition  
Low socioeconomic status  
Vegetarian diet  
Lack of balanced diet or poor intake  
Alcoholism  
Elderly 
High risk ethnic groups (First Nations, Indo-
Canadians*) 
Increased Loss Decreased Absorption 
Menorrhagia 
GI bleeding  
Regular blood donors 
Post-operative patients with significant blood 
loss 
Hematuria 
Intestinal parasites (travel or immigration from 
an endemic area) 
Hemolytic anemias  
Extreme physical exercise (endurance 
athletes) 
Dietary factors (tannins, phytates in fibre, 
calcium in milk, tea, coffee, carbonated drinks) 
Upper GI Pathology: • Chronic gastritis • 
Gastric lymphoma • Celiac disease • Crohn’s 
disease  
Medications that decrease gastric acidity or 
bind iron 
Gastrectomy or intestinal bypass 
Duodenal pathology 
Chronic renal failure 

Iron exchange 
Iron balance 
•  Iron enters the body by absorption from dietary sources in the 
duodenum. Iron circulates bound to transferrin and is delivered primarily 
to the bone marrow for erythropoiesis . Senescent erythrocytes are 
phagocytosed by reticuloendothelial macrophages to recycle iron back 
into  the circulation. Iron storage and release also occur in 
hepatocytes.Sloughing of enterocytes and bleeding are the only 
siginificant means for removing iron from the body. On average, 
approximately 1-2 mg of iron is provided on a daily basis by intestinal 
absorption, and this is balanced by an equal amount of iron loss by 
epithelial shedding in the gastrointestinal tract and blood loss in 
menstruating women. Most of the iron required for erythropoiesis, 
approximately 20-25 mg/d, is provided by iron recycling from senescent 
erythrocytes. The circulation pool of transferrin-bound iron is much 
smaller, approximately 3 mg, and therefore must be turned over every few 
hours to ensure an adequate supply of iron for erythropoiesis. 
Intestinal iron absorption 
• An individual enterocyte is depicted. 
• Dietary non-heme iron (Fe3+) must 
be reduced for transport across the 
apical brush border. DMT1 mediates 
proton-dependent Fe2+ import.  
• Dietary heme iron is transported by 
HCP1.  
• Once inside the cell, heme 
oxygenase releases iron from 
protoporphyrin, presumably allowing it 
to enter the same pool as non-heme 
iron.  
•Some iron is used or stored within the 
enterocyte in ferritin. This iron is later 
lost from the body when the intestinal 
mucosa is sloughed.  
•Some iron is exported across the 
basolateral membrane by ferroportin 
and oxidized to Fe3+ for incorporation 
into serum transferrin. 
The Transferrin Cycle 
• The liver synthesizes transferrin and secretes it into the plasma. Transferrins are 
produced locally in the testes and CNS. These two sites are relatively inaccessible to 
proteins in the general circulation (blood:testis barrier, blood:brain barrier)  
• When not bound to iron, it is known as "apotransferrin“ 
• Each transferrin molecule has the ability to carry two iron ions in the ferric form (Fe3+). 
• A transferrin binds to a transferrin receptor on the surface of a cell (e.g., to erythroid 
precursors in the bone marrow). Then it is transported into the cell in a vesicle by 
receptor-mediated endocytosis. The pH of the vesicle is reduced by hydrogen ion pumps 
(H+ ATPases) to about 5.5, causing transferrin to release its iron ions. The receptor (with 
its ligand, transferrin, bound) is then transported through the endocytic cycle back to the 
cell surface, ready for another round of iron uptake.  
Ferritin 
• Ferritin is a globular protein complex 
consisting of 24 protein subunits and is 
the primary intracellular iron-storage 
protein, keeping iron in a soluble and 
non-toxic form.  
• Ferritin that is not combined with iron 
is called apoferritin. 
• Each ferritin complex can store about 
4500 iron (Fe3+) ions. 
• The  heavy chain of Ferritin also 
possesses ferroxidase activity, this 
involves the conversion of iron from 
the ferrous (Fe2+) to ferric (Fe 3+) 
forms. This limits the deleterious 
reaction which occurs between ferrous 
iron and hydrogen peroxide known as 
the Fenton reaction which produces 
the highly damaging hydroxyl radical. 
 
 
Protective compensatory mechanism 
in chronic hypoxia 
There are several protective compensatory mechanism in chronic hypoxia 
followed by IDA: 
1. Activation of the protein complex - hypoxia-inducible factor 1 (HIF-1), 
which provides a physiological compensatory response to hypoxic stress by 
regulating the synthesis of erythropoietin, transferrin, and vascular 
endothelial growth factor, and the optimization of oxidative phosphorylation 
in the mitochondria.   
2. Activation of chemoreceptors and sympathetic-dependent 
vasoconstriction. Hypoxemia causes activation of chemoreceptors of carotid 
sinus, which in turn reflexively activate sympathetic-adrenal system. This 
leads to the release of catecholamines and arteriolar narrowing the skin, 
mucous membranes, muscles, abdomen and kidneys in order to reallocate 
tissue perfusion from'' no'' vital to vital organs (brain, heart).  
3. Increase cardiac output by increasing stroke output and increase in heart 
rate. This explains the often observed in IDA tachycardia. Initial oxygen 
starvation and an additional increase in oxygen demand of the heart with 
tachycardia provoke exacerbation of chronic heart disease, up to anginal 
attacks. 
 
 

Consequences of hypoxia 
Variety of metabolic disorders during hypoxia reduces 
to the basic pathogenic mechanisms such as: 
• Decrease of ATP synthesis as a result of failure of 
oxidative phosphorylation in the mitochondria.  
• As a result of deficit of ATP violation of all energy-
dependent cellular processes take place: synthesis of 
proteins, lipids, nucleic acids, the work of membrane 
ion channels, antioxidant protection.  
• Hypoxia is always accompanied by acidosis (due to 
the accumulation of lactic acid, pyruvate, etc.), which 
itself aggravates hypoxia - a vicious cycle develops. 
Clinical picture of ID and IDA 
Anemic syndrome 
Sideropenic 
syndrome 
Anemic syndrome 
Three pathogenetic mechanisms contribute to the anemic 
syndrome: 
1. Hemic hypoxia: refers to the decrease in amount of 
Hb in the blood. 
2. Tissue hypoxia which is the reduction of oxygen 
supply to a tissue below physiological levels despite 
adequate perfusion of the tissue by blood. 
3. Decreased viscosity of blood (systolic murmur at the 
apex and noise in the jugular veins) 
 
Symptoms of anemic syndrome 
Organs and systems Hemic hypoxia  Tissue hypoxia  
Respiratory system •Dyspnea  Dyspnea  
Cardiovascular system - •Heart pain 
•Palpitations  
•Heart failure 
Central and 
peripheral nervous 
system 
- •Feeling of lack of air, especially in 
unventilated areas  
•Fatigue 
•Headaches 
•Daytime sleepiness 
•Dizziness 
•Fainting  
Skin and mucous 
layers 
•Pallor •Hypersensitivity to cold 
•Chilliness  
Skeletal muscles - •Weakness 
•Fatigue during exercise 
Conjunctival pallor 
Due to vasoconstriction of the arterioles of the skin and 
mucous membranes  a pallor of skin, palmar creases 
and conjunctiva appears.  
http://www.ncbi.nlm.nih.gov/pmc/articl
es/PMC1497067/figure/fig2/ 
Pale conjunctiva. Note that the color 
of the pale anterior rim and the 
posterior part of the conjunctiva are 
the same. 
Normal conjunctiva. Note the full 
reddness of the anterior rim and its 
dissimilarity to the posterior aspect 
of the conjunctiva 
Sideropenic syndrome 
Sideropenic syndrome is caused by reduction in the synthesis 
of iron-containing proteins (hemoglobin, myoglobin, ferritin, 
hemosiderin, etc.) and decreased activity of iron-containing 
enzymes (cytochrome c reductase, succinate dehydrogenase, 
myeloperoxidase, etc.). This results in a dystrophic and atrophic 
processes followed in almost all cells.  
The symptoms are: 
• Symptoms of lesion of rapidly dividing cells: mucous membranes, skin and 
bone marrow 
• Pica chlorotica 
• Sideropenic dysphagia or Plummer-Vinson syndrome 
• Sideropenic fever (some patients have long-term temperature increase to 
subfebrile values) 
• Central  and peripheral nervous systems symptoms such as irritability, poor 
memory, poor concentration, intolerance to areas with limited air circulation, 
restless leg syndrome.  
• Deep iron deficiency may be accompanied by muscle atrophy, decreased 
muscle strength, hypotension, sphincter deficiency (frequent urge to urinate, 
nocturnal enuresis, urinary incontinence when laughing or coughing). 
Symptoms of sideropenic syndrome  
Symptoms of lesion of rapidly dividing cells 
The epithelium of the 
skin and skin 
appendages 
The epithelium of 
lining mucosa 
Bone  marrow cells 
Dry, exfoliating, itchy 
skin•  
 Tendency to cracked 
skin 
Poorly healing 
wounds and injuries  
Angular stomatitis - 
inflammation in the 
corners of the mouth•  
Fragility, loss, early 
graying of hair•  
Thinning, brittle, dull 
nails,  koilonychia 
Sideropenic 
dysphagia  or 
Plummer-Vinson 
syndrome 
 Atrophic glossitis 
 Atrophic gastritis 
 Atrophic rhinitis 
Atrophy of the 
intestinal mucosa 
Decreasing the amount 
of hemoglobin in red 
blood cells 
 Decreasing the 
amount of red blood 
cells 
 Reduction of the 
phagocytic activity of 
neutrophils 
 Reduce the number of 
T-lymphocytes and/or 
reduction of their 
function 
Symptoms of sideropenic syndrome  
Pica chlorotica 
• Taste perversion or pica chlorotica characterized by an 
overwhelming desire to eat inedible (chalk, clay, sand, ice, salt, 
etc.).  
• Manifestations of the syndrome also include sideropenic 
perversion of the sense of smell - addiction to smells, which by 
most others are perceived as unpleasant (gasoline, kerosene, 
acetone, dyes, shoe polish, naphthalene, etc.).  
• The term «pica» comes from the Latin «pica» - magpie - a bird 
known for its indiscriminate eating habits. It is believed that the 
term was first introduced Byzantine physician Etius of Amide in 
the 6th century AD, in his textbook on obstetrics. Etius said: "At 
about the second month of pregnancy, there is a disorder called 
Pica, and derived from the names of magpie ... Women want 
different: some spicy foods, other – salty."  
• One should note that pica in most cases is a manifestation of 
iron deficiency, but sometimes it is a manifestation of zinc 
deficiency or mental disorders. 
Plummer-Vinson syndrome 
Sideropenic  dysphagia  
  The syndrome is association with: 
• Dysphagia (difficulty swallowing), due to upper esophageal webs 
• Iron deficiency anemia t it is not associated with anemia. 
 
 
The presence of mucous membranes and  
webs in the upper third of the esophagus. 
Angular cheilitis 
(synonims: angular stomatitis, bridou) 
Angular cheilitis is an inflammatory lesion at the labial commissure, or 
corner of the mouth, and often occurs bilaterally. The condition manifests 
as deep cracks or splits. 
http://sdk-center.ru/lechenie_stomatita.html 
Cheilitis  
http://www.graphicshunt.com/health/imag
es/plummer-vinson_syndrome-2219.htm 
Cheilitis is a medical condition involving inflammation of the lip 
Sideropenic glossitis 
Glossitis is inflammation of the tongue 
http://flipper.diff.org/app/items/info/1626 
Koilonychia 
Koilonychia, also known as "spoon nails”, is a nail disease that can be a sign of 
hypochromic anemia, especially iron-deficiency anemia. 
It refers to abnormally thin nails (usually of the hand) which have lost their 
convexity, becoming flat or even concave in shape.  
http://mrishaanshareef.blogspot.com/2008/10/finger-nails-to-predict-
health.html                             
Koilonychia 
     
Sideropenic skin changes  
Poorly healing wounds and injuries  
Sideropenic skin changes 
 Dry, exfoliating, itchy skin  
Diagnostics  
Stage Description  Laboratory findings 
Stage 1  
Pre-latent  iron 
deficiency 
Depleted iron 
stores 
There are depleted iron stores 
but increased iron absorption 
and normal serum iron and 
capacity to bind iron and 
transport in around the body. 
•Low ferritin 
•Depletion of bone 
marrow iron 
 
 
 
Stage 2  
Latent iron 
deficiency 
 
There are decreased iron serum 
levels and there is an increase in 
the capacity of binding and 
transporting iron. 
•Low transferrin 
saturation 
• Low serum iron 
• Raised serum 
transferrin 
• Normal haemoglobin 
Stage 3  
Iron deficiency 
anemia 
Features of stages 1+stages 
2+anemia 
•Low haemoglobin  
Stages of Iron Deficiency 
Pre-latent  iron deficiency 
laboratory markers 
Marker  Advantages  Limitations  Normal range 
Serum ferritin 
 
Quantitative , 
well 
standardized 
 
Affected by 
inflammation, 
liver disease 
45-340 ng/mL 
 
Bone-marrow 
iron 
 
Well 
established, 
high specificity 
 
Affected by 
EPO 
treatment, 
invasive, 
expensive 
Examination of bone marrow 
• The examination of Prussian blue–stained bone marrow aspirate for the 
presence or absence of histiocytic iron granules has been considered the 
“gold standard”  
• Iron appears as variously sized intracellular blue granules or wispy 
amorphous intracellular deposits. The complete absence of staining is 
considered to represent iron deficiency. 
There is no stainable iron.   
The specimen is diffusely pale red/pink, 
which is the color of the counterstain on this 
slide.   
http://www.rightdiagnosis.com/phil/html/iron-
deficiency-anemia/2656.html 
Normal iron stores are seen as dark blue-
staining material in the bone marrow.  
http://www.rightdiagnosis.com/phil/html/iron-
deficiency/2657.html 
Latent  iron deficiency laboratory markers 
Marker  Changes in ID Advantages Limitations Normal range 
Soluble 
transferrin 
receptor (sTfR), 
serum 
Increase  
 
Quantitative 
(tissue deficiency) 
unaffected by 
inflammation 
Patients with 
hemolysis or 
recent blood loss 
may have falsely 
elevated 
sTfR levels 
1.8 – 4.6 mg/L 
Transferrin, serum Increase  due to 
an increase in 
synthesis.  
High levels 
can be seen in 
pregnancy and 
during estrogen 
administration. 
200-400 mg/dL 
Transferrin 
Saturation 
Decrease less than 
20% 
Inexpensive 
Well established 
Wide diurnal 
variation, Low 
specificity 
Transferrin is  20-
45% saturated 
with iron.  
Serum iron 
(should always be 
interpreted in the 
context of other 
markers of ID) 
Decrease  Serum iron alone 
is unreliable due 
to physiologic  
diurnal variations 
50-150 ug/dL 
Iron deficiency anemia laboratory markers 
Marker  Changes in ID Normal range 
Erythrocyte count Decrease 3.8-5.2 x 1012 /liter (female) 
4.4-5.9 x 1012 /liter (male) 
Hemoglobin Decrease 
 
12-140 g/dL (female) 
130-150 g/dL (male) 
Hematocrit Decrease 
 
36-45% (female) 
42-50% (male) 
Mean Cell Volume (MCV) Decrease 
Microcytosis  
80-100 femtoliters (fl) 
Mean cell hemoglobin 
(MCH) 
is the average mass of 
hemoglobin per red blood 
cell  
Decrease 
Hypochromic   
27 to 31 picograms/cell 
Peripheral blood smear in iron-
deficiency anemia 
Microcytosis with hypochromasia (100× oil). Hypochromic and microcytic red 
blood cells are seen with occasional target cells. The small, mature 
lymphocyte can be used to size the red blood cells. Many of the red blood 
cells have increased central pallor (hypochromia).  
http://www.sciencedirect.com/science/article/pii/S0740257011000979 
Hemoglobin levels 
Haemoglobin levels to diagnose anaemia at sea level (g/l) (WHO 2010) 
Revised Hemoglobin levels 
Proposed lower limits of normal for hemoglobin concentration of the blood 
for white and black adults 
Group Hemoglobin, g/L 
White men, y 
20-59  
60+ 
 
137 
132 
White women, y 
20-49  
50+  
 
122 
122 
Black men, y 
20-59  
60+ 
 
129 
127 
Black women, y 
20-49  
50+ 
 
115 
115 
In 2006, Ernest Beutler and Jill Waalen criticized existing since 1968 the lower limit of normal 
hemoglobin for women and men, proposed by WHO. Based on the research database the 
third revision of the National Register of Health, USA (NHANES-III) and its own database 
Scripps-Kaiser, gathered in San Diego from 1998 to 2002, they have proposed new lower limits 
of hemoglobin for adults of different by sex and race 
http://bloodjournal.hematologylibrary.org/content/107/5/1747.full.pdf 
Management of iron deficiency  
Three main strategies can be applied in order to 
improve iron status in individuals and 
populations:  
• Dietary modification  
• Food fortification  
• Iron supplemetation 
   Determine and treat underlying cause 
Dietary modification  
• Dietary iron sources include meat, fish and poultry, lentils, dried beans, 
grain products, vegetables, dried fruit, and molasses.  
Dietary Factors That Enhance and Inhibit Iron Absorption 
Enhance: 
•Gastric acid 
•Ascorbic acid 
•Malic acid 
•Citric acid 
Inhibit: 
•Phosphate 
•Calcium 
•Tea (tannic acid) 
•Coffee 
•Colas 
•Soy protein 
•High doses of minerals 
•Bran/fiber 
Oral iron medicines representing 
different iron salts 
Percentage and amount of iron in some commonly used oral 
iron preparations 
Preparation  Iron compound  
(mg/tab)  
Elemental iron  
mg/tab (%)  
Fe-sulfate(hydrous)  300  60 (20%)  
Fe-sulfate(dried)  200  65 (32.5%)  
Fe-fumarate  200  66 (33%)  
Fe-gluconate  300  36 (12%)  
Fe-succinate  100  35 (35%)  
Fe-bisglycinate  300  60 (20%)  
Carbonyl iron  100  98 (98%)  
Na-feredetate  231  33 (14%)  
Side-effects after oral iron intake 
• The oral administration of iron can cause gastrointestinal side-
effects in some individuals such as epigastric discomfort, 
nausea, vomiting, constipation, and diarrhea. 
• The frequency of these side-effects is directly related to the 
dose of iron or % of elemental iron in tablet.  
• In addition, iron consumed with a meal is better tolerated 
than when it is taken on an empty stomach, although the 
amount of iron absorbed is reduced.  
• Also blackening of teeth and faeces may occur due to 
formation of iron sulfide and metallic taste.  
Doses of oral iron supplements for 
the treatment of IDA (WHO) 
Patients  Treatment  
(daily dose, 
mg) 
Prophylaxis  
(daily dose, 
mg) 
 
Duration 
/months 
Adults  120 60 3 
Pregnant  120 60 3 
Iron poisoning 
• After aspirin, the second commonest cause of 
accidental poisoning among small children is 
iron. 
• Most deaths occur in children, particularly 12 
to 14 months. As little as 1 to 2 gm of iron may 
cause death.  
• The colored sugar coating of many 
commercially available tablets may attract the 
child and he may consume them.  
http://www.ijmps.com/files/documents/2.3.2.pdf 
Parenteral iron therapy 
•    Parenteral medicines contain only trivalent iron. 
• Indication  for  parenteral  iron medicines are: 
1. intolerance to oral iron preparations 
2. severe iron deficiency where a rapid 
3. therapeutic effect is needed 
4. functional iron deficiency where the iron demand for haemoglobin 
synthesis exceeds the amount that can be mobilised from filled iron 
stores, e.g. 
5. anaemia of inflammation  
6. iron deficiency, where oral iron therapy is insufficient because of chronic 
blood loss 
7. malabsorption of iron due to intestinal disorders 
8. poor compliance to oral iron treatment  
9. risk of drug-drug interactions between 
10. oral iron and concomitant medication. 
There are three parenteral iron products:  
 1. Iron  dextran (Cosmofer, DexFerrum, Infed). A notable side effect is allergic 
reaction, which occurs in less than 1 on 100 treated patients, but may cause 
severe, sometimes fatal, complications, including loss of consciousness, 
collapse, difficulty breathing, hives, swelling, convulsions and severe low 
blood pressure (hypotension). 
2. Iron sucrose (Venofer) has an occurrence of allergic reactions of less than 1 
in 1000. A common side effect is taste changes, especially a metallic taste.  
Doses can be given up to 3 times a week. 
3. Iron carboxymaltose (trade name Ferinject) is a newer formulation of 
parenteral iron which is dextran free with the shell being fully metabolised 
in the body to simple sugars. The most common side effect are headaches 
which occur in 3.3%. It can be given over 15 minutes in doses up to 1,000 
mg and has been adopted in many hospitals due to the increased number of 
patients that can be treated as no test dose is required and the patient does 
not need to be monitored after a dose has been administered. 
• Parenteral iron causes the same therapeutic response as oral iron but can 
cause adverse effects, such as anaphylactoid reactions, serum sickness, 
thrombophlebitis and pain.  
 
Transfusion  
• Blood transfusions are helpful in the context 
of life threatening anaemia with haemoglobin 
level less that 50 g/dl.  
• The repeated use of blood transfusions needs 
a careful appraisal. Iron overload, immune 
modulation and sensitization to HLA antigens 
may occur. 6  
Prognosis 
• Prediction of iron deficiency and IDA depends on the cause. If 
iron deficiency and IDA are caused by alimentary deficiency - 
the prognosis is favorable, ie with adequate compensation for 
iron, a complete recovery.  
• However, the prognosis is poor, if the IDA is due to a 
untreatable disease such as gastrointestinal tumors.  
• When iron deficiency and IDA occur in the fetus and young 
children then the prognosis is poor - there are intrauterine 
growth retardation, delayed neuro-psychological and physical 
development in young children 
• Chronic IDA is rarely the cause of death, but severe hypoxia 
may aggravate concomitant pulmonary or cardiac disease.  
• Very rarely severe anemia causes anemic coma, when 
patients refuse from blood transfusions for religious reasons. 
 
Prevention  
• Prevention of IDA is divided into primary and secondary. 
• Primary prevention - is iron intake by persons at risk in order 
to prevent the development of IDA. 
• Secondary prevention - is iron intake by persons with IDA  and 
persons with  irremovable cause of IDA, in order to prevent 
recurrence of IDA. 
Anemia of chronic disease 
Definition 
•  Anaemia of chronic disease (ACD) is the second most prevalent after 
anaemia by iron deficiency.  
• It is characterized by inadequate erythrocyte 
production in the setting of low serum iron, 
low iron binding capacity, low transferrin, but 
normal or high serum ferritin with a preserved 
or even increased macrophage iron stores in 
the bone marrow.  
• The erythrocytes are usually normocytic and normochromic, but long 
standing anaemia can give rise to microcytic and hypochromic blood 
picture .  
Causes of anaemia of chronic 
disease Infections:  
• Tuberculosis  
• Viral infections including human immunodeficiency  
• viruses infection  
• Bacterial  
• Parasitic  
• Fungal  
Cancer  
• Haematologic  
• Solid tumours  
Autoimmune  
• Rheumatoid arthritis  
• Systemic lupus erythematosus  
• and connective tissue disorders  
• Vasculitis  
• Sarcoidosis  
• Inflammatory bowel disease  
Chronic renal disease and inflammation  
Miscellaneous  
• Chronic rejection after solid – organ transplantation 
Pathogenesis 
• A hall mark of anaemia of chronic disorder is an 
increased uptake and retention of iron within 
cells of the reticuloendothelial system. 
• This leads to subsequent limitation of the 
availability of iron for erythroid cells , and iron- 
restricted erythropoiesis.  
Pathogenesis 
Cytokines released by activated leukocytes and other cells exert multiple 
effects that contribute to the reduction in hemoglobin levels: (A) Induction of 
hepcidin synthesis in the liver (especially by interleukin-6 [IL-6].  
(B) Inhibition of erythropoietin release from the kidney (especially by 
interleukin-1β [IL-1β] and tumour necrosis factor α [TNFα]).  
(C) Direct inhibition of the proliferation of erythroid progenitors.  
(D) Augmentation of erythrophagocytosis by reticuloendothelial macrophages 
(by TNFα).  
Pathogenesis 
A proposed mechanism for the anemia of 
chronic disease (ACD) is shown here. In 
the presence of infection, inflammation, or 
malignancy, the macrophage is stimulated 
to produce Interleukin-6 (IL-6), which 
induces the production of hepcidin by the 
liver. Hepcidin, in turn, through its 
interaction with the iron export protein 
ferroportin, inhibits iron absorption from 
the gastrointestinal tract and decreases 
release of iron from macrophages. Both 
effects lead to the reduced plasma iron 
levels (hypoferremia) characteristic of 
ACD. 
Protective mechanism of ACD 
• Iron is an essential nutrient for proliferating 
microorganisms, and the sequestration of iron 
from microorganisms or tumour cells into the 
reticuloendothelial system is believed to be a 
potentially effective defense strategy to inhibit 
the growth of pathogen.  
Clinical manifestation 
• Most often the sign and symptoms seen in 
patients with ACD are referable to the 
underlying disease.  
• Common symptoms elicited from the history 
include weight loss, anorexia, fever,chills, 
myalagias and arthralgias.  
• The anaemia usually occurs insidiously over a 
period of approximately 3 to 4 weeks and 
therafter remains stable or unchanged. 
Laboratory Evaluation  
• ACD is a normochromic, normocytic anaemia that is 
characteristlcally mild (hameoglobin level ,9.5 g per 
deciliter) to moderate (haemoglobin level , 8 g per 
deciliter). Hematocrit: 28 ~ 32%.  
• ↓ Iron (hypoferremia) 
• ↓ Iron-binding capacity 
• ↓ Transferrin saturation  
• ↑ Ferritin     
• ↓ soluble transferrin receptor conc. 
• ↑ Hemosiderin within mactophages  
 
 

Treatment 
• Iron therapy: does not correct the anemia!  
• Recognition and correction of underlying 
disorders! 
• Erythropoietin administration. Purified 
recombinant erythropoietin (epoetin alfa) is 
effective for treatment of the anemia of renal 
failure and other secondary anemias such as 
anemia related to cancer or inflammatory 
disorders (eg, rheumatoid arthritis).  
Vitamin B 12 deficiency anemia 
Epidemiology  
• The prevalence of pernicious anemia ranges 
from 50 to 4000 cases per 100,000 persons, 
depending on the diagnostic criteria. 
• All age groups are affected, but the median 
age range in large series is 70 to 80 years. 
• Pernicious anemia is more common in persons 
of African or European ancestry. 
Pernicious anemia 
• Pernicious anemia is an autoimmune gastritis 
resulting from the destruction of gastric 
parietal cells and the associated lack of 
intrinsic factor to bind ingested vitamin B12. 
The immune response is directed against the 
gastric H/K–ATPase, which accounts for 
associated achlorhydria. 
Causes B 12 deficiency  
Sources of vitamin  В12 
• Vitamin B12 is produced 
by soil microbes that live in 
symbiotic relationships with 
plant roots 
•Vitamin B12 is found only 
in foods of animal origin in 
meat, liver, kidney, eggs, 
cheese, milk. 
•B12 in human milk is 
contained in the form of 
methylcobalamin (the main 
form of the vitamin in the 
body). 
Vitamin B12 contains cobalt in 
its structure and a cyano group, 
each together  forming a  
cyanocobalamin. 
The human body does not 
synthesize B12.  
Body`s demands for vitamin B 
• The daily requirement of vitamin B12 has been set at 2.4 μg 
• Total stores of B12 in the adult human body is about 2-5 mg. 
• Stores B12 in the body are large, so that the deficit occurs 
only after 5-6 years after decrease of intake 
• The daily intake is about 9.6 mg 
• The daily output is about 2.5 mg with urine and feces. 
•  Principal place of deposit of vitamin B12 is the liver. Large 
amount is absorbed as the spleen and kidney, somewhat less - 
muscles. 
 
Folate/B12 DNA Synthesis 
Methylmalonic acid 
• Patients with cobalamin deficiency have 
increased concentrations of MMA in their 
serum (S-MMA) because 5’-
deoxyadenosylcobalainin is required for the 
enzymatic conversion of I-methylmalonyl-CoA 
to succinyl-CoA by methylmalonyl-CoA mutase.  
• An increased concentration of MMA in serum 
and its excessive urinary excretion are believed 
to be direct measures of tissue stores of 
cobalamin and thus provide an indication of 
functional cobalamin deficiency. 
Absorption of Vitamin B12 
– Dietary B-12 binds to haptocorrin (HC) (R factor) in saliva and 
gastric juices.  
– Haptocorrin  is  produced by the salivary glands of the oral 
cavity, in response to ingestion of food 
– The essential function of haptocorrin is protection of the acid-
sensitive vitamin B12 while it moves through the stomach. 
– In duodenum, pancreatic enzymes promote dissociation from 
HC to bind to Intrinsic Factor (IF) 
– IF-B12 complex taken up by ileal receptor cubilin. 
– Released into plasma bound to transcobalamines TC I, II, III 
and haptocorrin. 
–  Haptocorrin binds approximately 80% of circulating B12, 
rendering it unavailable for cellular delivery by 
Transcobalamin II. 
 
Absorption of Vitamin B12 
Clinical signs 
The Triad: 
1.Blood disturbances 
2.Gastrointestinal lesions 
3.Damage of CNS and PNS 

Diagnostics  
Changes in blood  
1. Reduction in the number of erythrocytes and decrease of 
hemoglobin level   
2. Prevalence of macrocytes (diameter> 8 mcm, MCV> 100 fl) 
and megalocytes (diameter of 10 to 12 mcm) in blood smear 
3. The increase in color index greater than 1.0  (hyperchromic 
RBC, MCH> 34 pg). 
4. Cabot rings and Howell–Jolly bodies  
5. Anisocytosis, poikilocytosis  
6. Large number of makroovalocytes. 
7. Reduced number of reticulocytes  
8. Leukopenia  
9. Neutropenia with a shift to the right (presence of overmature 
hypersegmented neutrophils > 5%) 
10.Eosinopenia 
11.Monotsitopeniya and relative lymphocytosis 
12.Thrombocytopenia 
Cabot rings and Howell–Jolly 
bodies  
•Cabot rings are thin, red-violet staining, threadlike strands in the shape of a 
loop or figure-8 that are found on rare occasions in erythrocytes.  
•Howell–Jolly bodies are histopathological findings of basophilic nuclear 
remnants (clusters of DNA) in circulating erythrocytes.  
Hypersegmented neutrophil  
Hypersegmented neutrophil  
Macro-ovalocytes, basophilic stippling, 
and bizarre-shaped red cell forms 
Vitamin B12 deficiency. (Peripheral blood, 100 x.) Shown are several hallmark 
features of vitamin B12 deficiency, including macro-ovalocytes, basophilic 
stippling, and bizarre-shaped red cell forms. (Courtesy of L Damon.) 
Macroovalocytosis  
Megaloblastic erythropoesis 
Laboratory confirmation of 
diagnosis  
Marker  В12-anemia  Norm 
Serum vitamin B12 < 200 pg/ml 200-900 pg/ml 
 
Serum methylmalonic 
acid 
>0.75 µmol/l 0.07 - 0.27 
µmol/l 
Serum or plasma total 
homocysteine  
>21 µmol/liter 2.2 - 13.2 µmol/l 
Tests to determine cause of deficiency  
Marker  В12-anemia  Norm 
Anti–intrinsic factor 
antibodies  
Present  Absent  
Anti–parietal-cell 
antibodies 
Present  Absent  
Fasting high serum 
gastrin level  
>100 pmol/liter 
Low level of serum 
pepsinogen I 
<30 µg/liter 
Treatment  
Saturation phase  
4-6 weeks 
Fixating phase 
6 month 
Maintenance phase 
lifelong 
• Vitamin B12 is administered orally, intramuscularly, 
intravenously and intralumbarly. 
• Different forms of vitamin B12 can be used, including cyano,- 
hydroxy,- and methylcobalamin.  
 
 
Injected Vitamin B12 
• About 10% of the injected dose (100 of 1000 μg) is 
retained.  
• Patients with severe abnormalities should receive 
injections of 1000 μg at least several times per week 
for 1 to 2 weeks, then weekly until clear 
improvement is shown, followed by monthly 
injections.  
High-Dose Oral Treatment 
• High-dose oral treatment is effective and is 
increasingly popular.  
• 0.5 to 4% of radioactively labeled oral vitamin B12 
can be absorbed by passive diffusion in both normal 
controls and patients with pernicious anemia. 
• Thus, oral doses of 1000 μg deliver 5 to 40 μg, even if 
taken with food. 
Response to treatment 
• Hematologic response is rapid, with an increase in the 
reticulo-cyte count in 1 week and correction of 
megalo-blastic anemia in 6 to 8 weeks.  
The end 
